Aventis Pharma S.a.

Sanofi-a Ventis Deutschland Gmbh

Christine Delaisi

Karl Schoenafinger

Hans Matter

David William Will

Anke Steinmetz

Swen Hoelder

Ingrid Sassoon

Gunter Muller

Cecile Combeau

Martin Bossart

Didier Benard

Günter Müller

Cécile Combeau

Disclosed are compounds of Formula I wherein X is and R, R, A, B, D, E, Rare as defined herein useful for treating cancers.

Pyridazinone kinase inhibitors

Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, Rand Rare detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

4-benzimidazol-2-ylpyridazin-3-one derivatives

Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, Rand Rare detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals.  These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).

Pyridazinone derivatives

Growing community of inventors

Saint Maur, France

Christine Delaisi